Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group.

N Engl J Med. 2007 Jul 5;357(1):28-38. Epub 2007 Jun 5.

2.

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Nissen SE, Wolski K.

N Engl J Med. 2007 Jun 14;356(24):2457-71. Epub 2007 May 21. Erratum in: N Engl J Med. 2007 Jul 5;357(1):100..

3.

Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.

Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K; ONTARGET/TRANSCEND Investigators.

Circulation. 2007 Mar 20;115(11):1371-5. Epub 2007 Mar 5.

4.

Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy.

Masoudi FA, Inzucchi SE.

Am J Cardiol. 2007 Feb 19;99(4A):113B-132B. Epub 2006 Dec 22. Review.

PMID:
17307064
5.

A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin.

Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM.

Diabetes Care. 2007 Feb;30(2):389-94.

PMID:
17259518
6.

Osteoporosis-related kyphosis and impairments in pulmonary function: a systematic review.

Harrison RA, Siminoski K, Vethanayagam D, Majumdar SR.

J Bone Miner Res. 2007 Mar;22(3):447-57. Review.

7.

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group.

N Engl J Med. 2006 Dec 7;355(23):2427-43. Epub 2006 Dec 4. Erratum in: N Engl J Med. 2007 Mar 29;356(13):1387-8.

8.

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR.

Lancet. 2006 Sep 23;368(9541):1096-105. Erratum in: Lancet. 2006 Nov 18;368(9549):1770.

9.

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.

Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA.

CMAJ. 2006 Jan 17;174(2):169-74.

10.
11.

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators.

Lancet. 2005 Oct 8;366(9493):1279-89.

PMID:
16214598
12.

The PROactive study: some answers, many questions.

Yki-Järvinen H.

Lancet. 2005 Oct 8;366(9493):1241-2. No abstract available.

PMID:
16214581
13.

Pioglitazone initiation and subsequent hospitalization for congestive heart failure.

Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM.

Diabet Med. 2005 Aug;22(8):986-93.

14.

A systematic review of drug therapy to delay or prevent type 2 diabetes.

Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA.

Diabetes Care. 2005 Mar;28(3):736-44. Review.

PMID:
15735219
15.

Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting.

Maru S, Koch GG, Stender M, Clark D, Gibowski L, Petri H, White AD, Simpson RJ Jr.

Diabetes Care. 2005 Jan;28(1):20-6.

PMID:
15616228
16.

The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.

Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudtson ML; APPROACH Investigators.

J Am Coll Cardiol. 2004 Oct 19;44(8):1587-92.

17.
18.

The incidence of congestive heart failure associated with antidiabetic therapies.

Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB.

Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):51-7.

PMID:
15386819
19.

The incidence of congestive heart failure in type 2 diabetes: an update.

Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB.

Diabetes Care. 2004 Aug;27(8):1879-84.

PMID:
15277411

Supplemental Content

Support Center